All In Biotech

Drug Trial Radar · NCT05764538

DAOIB for the Treatment of Brain Fog

DAOIB for the Treatment of Cognitive Impairment Induced by COVID-19 -An Open Trial

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Feb 27, 2023

Primary completion

Jun 2027

Study completion Jun 2027

Sponsor

Lead sponsor
Chang Gung Memorial HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 24-week open trial. We will enroll long-COVID patients with cognitive impairments. All patients will receive DAOIB for 24 weeks. We will assess the patients every 8 weeks during the treatment period (weeks 0, 8, 16, and 24). We hypothesize that DAOIB treatment will be beneficial in improving the cognitive function, mood symptoms, global functioning and quality of life in long-COVID patients with cognitive impairments.

Conditions

  • Long COVID

Interventions

  • DAOIBDrug

    The DAOIB dose will be adjusted every 8 weeks according to clinical evaluation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in the Alzheimer's disease assessment scale - cognitive subscale at week 8, 16 and 24Time frame: week 0, 8, 16, 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Kaohsiung Chang Gung Memorial Hospital

    Kaohsiung City, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.